393 related articles for article (PubMed ID: 20733951)
1. Urine cytology and adjunct markers for detection and surveillance of bladder cancer.
Sullivan PS; Chan JB; Levin MR; Rao J
Am J Transl Res; 2010 Jul; 2(4):412-40. PubMed ID: 20733951
[TBL] [Abstract][Full Text] [Related]
2. Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer.
Lotan Y; Baky FJ
Urol Clin North Am; 2023 Feb; 50(1):53-67. PubMed ID: 36424083
[TBL] [Abstract][Full Text] [Related]
3. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
4. Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma.
Jackson J; Barkan GA; Kapur U; Wojcik EM
Cancer Cytopathol; 2013 Jul; 121(7):398-402. PubMed ID: 23364860
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Value of Combined Urine Cytology and Cystoscopy for Follow-up of Superficial Transitional Cell Carcinoma of the Urinary Bladder.
Tahoun NS; Abdel Maksoud AM; Mohamed DB
J Egypt Natl Canc Inst; 2010 Jun; 22(2):105-11. PubMed ID: 21860467
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers for the early detection of bladder cancer.
Han KR; Pantuck AJ; Belldegrun AS; Rao JY
Front Biosci; 2002 Jan; 7():e19-26. PubMed ID: 11779696
[TBL] [Abstract][Full Text] [Related]
7. Urine markers for detection and surveillance of bladder cancer.
Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF
Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865
[TBL] [Abstract][Full Text] [Related]
8. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.
Schlake A; Crispen PL; Cap AP; Atkinson T; Davenport D; Preston DM
Can J Urol; 2012 Aug; 19(4):6345-50. PubMed ID: 22892257
[TBL] [Abstract][Full Text] [Related]
9. Comparing CxBladder to Urine Cytology as Adjunct to Cystoscopy in Surveillance of Non-muscle Invasive Bladder Cancer-A Pilot Study.
Chai CA; Yeoh WS; Rajandram R; Aung KP; Ong TA; Kuppusamy S; Nazran A; Kumaran K; Razack AHA; Teoh JY
Front Surg; 2021; 8():659292. PubMed ID: 34055868
[No Abstract] [Full Text] [Related]
10. The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results.
Curry JL; Wojcik EM
Cancer; 2002 Jun; 96(3):140-5. PubMed ID: 12115301
[TBL] [Abstract][Full Text] [Related]
11. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
12. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
[TBL] [Abstract][Full Text] [Related]
13. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
14. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
15. Genitourinary cytopathology (kidney and urinary tract).
Barkan GA; Wojcik EM
Cancer Treat Res; 2014; 160():149-83. PubMed ID: 24092370
[TBL] [Abstract][Full Text] [Related]
16. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer.
Yafi FA; Brimo F; Auger M; Aprikian A; Tanguay S; Kassouf W
Urol Oncol; 2014 Jan; 32(1):27.e1-6. PubMed ID: 23410943
[TBL] [Abstract][Full Text] [Related]
17. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
18. Is a consistent cytologic diagnosis of low-grade urothelial carcinoma in instrumented urinary tract cytologic specimens possible? A comparison between cytomorphologic features of low-grade urothelial carcinoma and non-neoplastic changes shows extensive overlap, making a reliable diagnosis impossible.
McCroskey Z; Kliethermes S; Bahar B; Barkan GA; Pambuccian SE; Wojcik EM
J Am Soc Cytopathol; 2015; 4(2):90-97. PubMed ID: 31051715
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.
Toma MI; Friedrich MG; Hautmann SH; Jäkel KT; Erbersdobler A; Hellstern A; Huland H
World J Urol; 2004 Jun; 22(2):145-9. PubMed ID: 14991320
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art.
Williamson SR; Montironi R; Lopez-Beltran A; MacLennan GT; Davidson DD; Cheng L
Crit Rev Oncol Hematol; 2010 Nov; 76(2):112-26. PubMed ID: 20097572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
